594 related articles for article (PubMed ID: 11486167)
21. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.
Castilla C; Congregado B; Conde JM; Medina R; Torrubia FJ; Japón MA; Sáez C
Urology; 2010 Oct; 76(4):1017.e1-6. PubMed ID: 20708221
[TBL] [Abstract][Full Text] [Related]
22. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
[TBL] [Abstract][Full Text] [Related]
24. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
25. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
26. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome.
Ross JS; Figge HL; Bui HX; del Rosario AD; Fisher HA; Nazeer T; Jennings TA; Ingle R; Kim DN
Mod Pathol; 1994 Oct; 7(8):835-41. PubMed ID: 7530850
[TBL] [Abstract][Full Text] [Related]
27. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Umbas R; Isaacs WB; Bringuier PP; Schaafsma HE; Karthaus HF; Oosterhof GO; Debruyne FM; Schalken JA
Cancer Res; 1994 Jul; 54(14):3929-33. PubMed ID: 7518346
[TBL] [Abstract][Full Text] [Related]
28. [Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer].
Huang X; Zhou LQ; Ai JK; Lu YQ; Bai Y; Zeng L; Zhang ZW; Guo YL
Ai Zheng; 2002 Nov; 21(11):1208-11. PubMed ID: 12526217
[TBL] [Abstract][Full Text] [Related]
29. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
30. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
31. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
32. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases.
Hull D; Ma J; Singh H; Hossain D; Qian J; Bostwick DG
BJU Int; 2009 Oct; 104(7):915-8. PubMed ID: 19388995
[TBL] [Abstract][Full Text] [Related]
33. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
34. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival.
Lazăr D; Tăban S; Ardeleanu C; Dema A; Sporea I; Cornianu M; Lazăr E; Vernic C
Rom J Morphol Embryol; 2008; 49(4):459-67. PubMed ID: 19050793
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
36. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.
Chetty R; Serra S; Asa SL
Am J Surg Pathol; 2008 Mar; 32(3):413-9. PubMed ID: 18300809
[TBL] [Abstract][Full Text] [Related]
37. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
38. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
Kang GH; Lee S; Lee HJ; Hwang KS
J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
[TBL] [Abstract][Full Text] [Related]
39. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
40. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]